<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Antituberculous drugs; Tuberculosis; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Streptomycin; Rifater; Ethambutol; Rifinah; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; DOT (directly observed therapy); Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Mycobacterium avium complex infections; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Rifamycins; Rifabutin; Pyrazinamide; Ethambutol; Streptomycin; Amikacin: tuberculosis; Capreomycin; Cycloserine; Prothionamide see Protionamide; Protionamide" /><meta name="IX" content="Antituberculous drugs; Tuberculosis; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Streptomycin; Rifater; Ethambutol; Rifinah; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; DOT (directly observed therapy); Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Mycobacterium avium complex infections; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Rifamycins; Rifabutin; Pyrazinamide; Ethambutol; Streptomycin; Amikacin: tuberculosis; Capreomycin; Cycloserine; Protionamide" /><meta name="IXN" content="Prothionamide see Protionamide" /><title>5.1.9 Antituberculosis drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="3899.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="3899.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=3899.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2071.htm">5 Infections</a> &gt; <a href="3705.htm">5.1 Antibacterial drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3894.htm" title="Previous: TRIMETHOPRIM">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="3900.htm" title="Next: CAPREOMYCIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_3899">5.1.9 Antituberculosis drugs</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i199.htm" title="Go to appendix 1">Rifamycins</a>).</div><div><p>Tuberculosis is treated
in two phases—an <i>initial phase</i> using 4 drugs and
a <i>continuation phase</i> using 2 drugs in fully sensitive
cases. Treatment requires specialised knowledge, particularly where
the disease involves resistant organisms or non-respiratory organs.</p><p>The regimens given below are recommended for the treatment of
tuberculosis in the UK; variations occur in other countries. Either
the unsupervised regimen or the supervised regimen described below
should be used; the two regimens should <b>not</b> be used
concurrently. </p><div class="cAZ"><h2>Initial phase</h2> <p class="cAX">The concurrent use of 4 drugs during
the initial phase is designed to reduce the bacterial population as
rapidly as possible and to prevent the emergence of drug-resistant
bacteria. The drugs are best given as combination preparations unless
one of the components cannot be given because of resistance or intolerance.
The treatment of choice for the initial phase is the daily use of <span>isoniazid</span>, <span>rifampicin</span>, <span>pyrazinamide</span> and ethambutol. Treatment
should be started without waiting for culture results if clinical
features or histology results are consistent with tuberculosis; treatment
should be continued even if initial culture results are negative.
The initial phase drugs should be continued for 2 months. Where a
positive culture for <span class="cAC">M. tuberculosis</span> has been
obtained, but susceptibility results are not available after 2 months,
treatment with <span>rifampicin</span>, <span>isoniazid</span>, <span>pyrazinamide</span> and ethambutol should be continued
until full susceptibility is confirmed, even if this is for longer
than 2 months.</p><p><span>Streptomycin</span> is rarely used in the UK but it may be used in the initial phase
of treatment if resistance to <span>isoniazid</span> has been
established before therapy is commenced.</p></div><div class="cAZ"><h2>Continuation phase</h2> <p class="cAX">After the initial phase, treatment
is continued for a further 4 months with <span>isoniazid</span> and <span>rifampicin</span> (preferably given as a combination
preparation). Longer treatment is necessary for meningitis, direct
spinal cord involvement, and for resistant organisms which may also
require modification of the regimen.</p></div><div class="cAZ"><h2>Unsupervised treatment</h2> <p class="cAX">The following regimen should
be used for patients who are likely to take antituberculous drugs
reliably <b>without supervision</b>. Patients who are unlikely
to comply with daily administration of antituberculous drugs should
be treated with the regimen described under Supervised Treatment. </p></div><div class="cBM" id="_tb0066">Recommended dosage for standard unsupervised 6-month treatment</div><table class="table" summary="Recommended dosage for standard unsupervised 6-month treatment" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><tbody><tr><td style="" colspan="2"><i>2-month initial phase</i></td></tr><tr><td style=""> </td><td class="auto-generated" style=""> </td></tr><tr><td style=""><i><b>Rifater</b>®</i> [rifampicin, isoniazid, and pyrazinamide]</td><td style=""><span class="cAK">adult</span> body-weight under 40 kg 3 tablets daily; body-weight 40–49 kg 4 tablets daily; body-weight 50–64 kg 5 tablets daily; body-weight over 65 kg 6 tablets daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b>Ethambutol </b></td><td style=""><span class="cAK">adult</span> and <span class="cAK">child</span> 15 mg/kg daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style="" colspan="2"><i>4-month continuation phase following initial treatment with Rifater® and ethambutol</i></td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><i><b>Rifinah</b>®</i>[rifampicin and isoniazid]</td><td style=""><span class="cAK">adult</span> body-weight under 50 kg 3 tablets daily of <i>Rifinah</i>® <i>150/100</i>; body-weight 50 kg and over 2 tablets daily of <i>Rifinah</i>® <i>300/150</i></td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style="" colspan="2"><i>or</i> (if combination preparations not appropriate):</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b><span>Isoniazid</span></b> (for 6 months)</td><td style=""><span class="cAK">adult</span> 300 mg daily; <span class="cAK">child</span> 10 mg/kg (max. 300 mg) daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b><span>Rifampicin</span></b> (for 6 months)</td><td style=""><span class="cAK">adult</span> body-weight under 50 kg 450 mg daily; body-weight 50 kg and over 600 mg daily; <span class="cAK">child</span> 10 mg/kg daily (max. 450 mg daily if body-weight under 50 kg; max. 600 mg daily if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b><span>Pyrazinamide</span></b> (for 2-month initial phase only)</td><td style=""><span class="cAK">adult</span> body-weight under 50 kg 1.5 g daily; body-weight 50 kg and over 2 g daily; <span class="cAK">child</span> 35 mg/kg daily (max. 1.5 g daily if body-weight under 50 kg; max. 2 g daily if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b>Ethambutol</b> (for 2-month initial phase only)</td><td style=""><span class="cAK">adult</span> and <span class="cAK">child</span> 15 mg/kg daily</td></tr></tbody></table><div id="_120606"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">The standard regimen (above) may be
used during pregnancy. <span>Streptomycin</span> should
not be given in pregnancy.</p></div></div><div id="_208825"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">The standard regimen (above) may
be used during breast-feeding</p></div></div><div class="cAZ"><h2>Children</h2> <p class="cAX">Children are given <span>isoniazid</span>, <span>rifampicin</span>, <span>pyrazinamide</span>,
and ethambutol for the first 2 months followed by <span>isoniazid</span> and <span>rifampicin</span> during the next 4 months. However, care is needed in young children receiving ethambutol because of
the difficulty in testing eyesight and in obtaining reports of visual
symptoms (see below).</p></div><div class="cAZ"><h2>Supervised treatment</h2> <p class="cAX">Drug administration needs
to be <b>fully supervised</b> (directly observed therapy, DOT) in patients
who cannot comply reliably with the treatment regimen. These patients
are given <span>isoniazid</span>, <span>rifampicin</span>, <span>pyrazinamide</span> and ethambutol (or <span>streptomycin</span>) 3 times a week under supervision for the first 2 months followed
by <span>isoniazid</span> and <span>rifampicin</span> 3
times a week for a further 4 months.</p></div><div class="cBM" id="_tb0067">Recommended dosage for intermittent supervised 6-month treatment</div><table class="table" summary="Recommended dosage for intermittent supervised 6-month treatment" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><tbody><tr><td style=""><b><span>Isoniazid</span></b> (for 6 months)</td><td style=""><span class="cAK">adult</span> and <span class="cAK">child</span> 15 mg/kg (max. 900 mg) 3 times a week</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b><span>Rifampicin</span></b> (for 6 months)</td><td style=""><span class="cAK">adult</span> 600–900 mg 3 times a week; <span class="cAK">child</span> 15 mg/kg (max. 900 mg) 3 times a week</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b><span>Pyrazinamide</span></b> (for 2-month initial phase only)</td><td style=""><span class="cAK">adult</span> body-weight under 50 kg 2 g 3 times a week; body-weight 50 kg and over 2.5 g 3 times a week; <span class="cAK">child</span> 50 mg/kg 3 times a week (max. 2 g 3 times a week if body-weight under 50 kg; max. 2.5 g 3 times a week if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><b>Ethambutol</b> (for 2-month initial phase only)</td><td style=""><span class="cAK">adult</span> and <span class="cAK">child</span> 30 mg/kg 3 times a week</td></tr></tbody></table><div class="cAZ"><h2>Immunocompromised patients</h2> <p class="cAX">Multi-resistant <span class="cAC">Mycobacterium tuberculosis</span> may be present in immunocompromised
patients. The organism should always be cultured to confirm its type
and drug sensitivity. Confirmed <span class="cAC">M. tuberculosis</span> infection sensitive to first-line drugs should be treated with a
standard 6-month regimen; after completing treatment, patients should
be closely monitored. The regimen may need to be modified if infection
is caused by resistant organisms, and specialist advice is needed.</p><p>Specialist advice should be sought about tuberculosis
treatment or chemoprophylaxis in a HIV-positive individual; care is required in choosing the regimen and in avoiding potentially
serious interactions. Starting antiretroviral treatment in the first
2 months of antituberculosis treatment increases the risk of immune
reconstitution syndrome.</p><p>Infection may also be caused by other mycobacteria e.g. <span class="cAC">M. avium</span> complex in which case specialist advice
on management is needed.</p></div><div class="cAZ"><h2>Corticosteroids</h2> <p class="cAX">In meningeal or pericardial tuberculosis,
a corticosteroid should be started at the same time as antituberculosis
therapy. </p></div><div class="cAZ"><h2>Prevention of tuberculosis</h2> <p class="cAX">Some individuals may
develop tuberculosis owing to reactivation of previously latent disease.
Chemoprophylaxis may be required in those who have evidence of latent
tuberculosis and are receiving treatment with immunosuppressants (including
cytotoxics and possibly long-term treatment with systemic corticosteroids).
In these cases, chemoprophylaxis involves use of either <span>isoniazid</span> alone for 6 months or of <span>isoniazid</span> and <span>rifampicin</span> for 3 months, see Table 2, <a title="sub-topic: Table 2 TB prophylaxis" href="102055.htm#_102055"> section 5.1</a>; longer chemoprophylaxis is not
recommended. </p><p>For prevention of tuberculosis in susceptible close contacts
or those who have become tuberculin-positive, see Table 2, <a title="sub-topic: Table 2 TB prophylaxis" href="102055.htm#_102055">section 5.1</a>. For advice on immunisation against
tuberculosis, see <a title="monograph-family: BCG vaccines" href="6457.htm#_6457">section 14.4</a></p></div><div id="_3899.1"><div class="cAZ"><h2>Monitoring</h2> <p class="cAX">Since <span>isoniazid</span>, <span>rifampicin</span> and <span>pyrazinamide</span> are associated
with liver toxicity, <i>hepatic function</i> should be checked before treatment with these drugs. Those with pre-existing
liver disease or <span>alcohol</span> dependence should have
frequent checks particularly in the first 2 months. If there is no
evidence of liver disease (and pre-treatment liver function is normal),
further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice
or unexplained deterioration during treatment. In view of the need
to comply fully with antituberculous treatment on the one hand and
to guard against serious liver damage on the other, patients and their
carers should be informed carefully how to recognise signs of liver
disorders and advised to discontinue treatment and seek <b>immediate</b> medical attention should symptoms of liver disease occur.</p><p><i>Renal function</i> should be checked
before treatment with antituberculous drugs and appropriate
dosage adjustments made. <span>Streptomycin</span> or ethambutol
should preferably be avoided in patients with renal impairment, but
if used, the dose should be reduced and the plasma-drug concentration
monitored.</p><p><i>Visual acuity</i> should be tested before ethambutol
is used (see below).</p></div></div><div class="cN"><p>Major causes of treatment failure are incorrect prescribing
by the physician and inadequate compliance by the patient. Monthly
tablet counts and urine examination (<span>rifampicin</span> imparts an orange-red coloration) may be useful indicators of compliance
with treatment. Avoid both excessive and inadequate dosage. Treatment
should be supervised by a specialist physician.</p></div><div id="_218825"><p><b><span>Isoniazid</span></b> is cheap and highly effective. Like <span>rifampicin</span> it should always be included in any antituberculous regimen unless
there is a specific contra-indication. Its only common side-effect
is peripheral neuropathy which is more likely to occur where there
are pre-existing risk factors such as diabetes, <span>alcohol</span> dependence, chronic renal failure, pregnancy, malnutrition and HIV infection. In these circumstances pyridoxine 10 mg daily (or 20 mg daily if
suitable product not available) (<a title=" Vitamin B group" href="5100.htm#_5100">section 9.6.2</a>) should be given prophylactically from the start
of treatment. Other side-effects such as hepatitis (important: see
Monitoring above) and psychosis are rare.</p></div><p><b><span>Rifampicin</span></b>, a rifamycin, is a key component
of any antituberculous regimen. Like <span>isoniazid</span> it
should always be included unless there is a specific contra-indication.</p><div id="_3899.2"><p>During the first two months (‘initial phase’) of <span>rifampicin</span> administration transient disturbance of liver function with elevated
serum transaminases is common but generally does not require interruption
of treatment. Occasionally more serious liver toxicity requires a
change of treatment particularly in those with pre-existing liver
disease (important: see Monitoring above).</p></div><p>On intermittent treatment six toxicity syndromes
have been recognised—influenza-like, abdominal, and respiratory symptoms,
shock, renal failure, and thrombocytopenic purpura—and can occur in
20 to 30% of patients.</p><p><span>Rifampicin</span> induces hepatic enzymes which
accelerate the metabolism of several drugs including oestrogens, <span>corticosteroids</span>, <span>phenytoin</span>, sulfonylureas,
and anticoagulants; <b>interactions:</b> Appendix 1 (rifamycins). <b>Important:</b> the effectiveness of hormonal contraceptives
is reduced and alternative family planning advice should be offered (<a title=" Combined oral contraceptives" href="4552.htm#_4552">section 7.3.1</a>).</p><p><b><span>Rifabutin</span></b>, another rifamycin, is indicated for <i>prophylaxis</i> against <span class="cAC">M. avium</span> complex infections in patients
with a low CD4 count; it is also licensed for the <i>treatment</i> of non-tuberculous mycobacterial disease and pulmonary tuberculosis. <b>Important:</b> as with <span>rifampicin</span> it induces
hepatic enzymes and the effectiveness of hormonal contraceptives
is reduced requiring alternative family planning methods.</p><p><b><span>Pyrazinamide</span></b> [unlicensed] is a bactericidal drug
only active against intracellular dividing forms of <span class="cAC">Mycobacterium
tuberculosis</span>; it exerts its main effect only in the first
two or three months. It is particularly useful in tuberculous meningitis
because of good meningeal penetration. It is not active against <span class="cAC">M. bovis</span>. Serious liver toxicity may occasionally occur
(important: see Monitoring above).</p><p><b>Ethambutol</b> is included in a treatment regimen if <span>isoniazid</span> resistance is suspected; it can be omitted if the risk of resistance
is low. </p><div id="_3899.3"><p>Side-effects of ethambutol are largely confined to visual disturbances
in the form of loss of acuity, colour blindness, and restriction of
visual fields. These toxic effects are more common where excessive
dosage is used or if the patient’s renal function is impaired. The
earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if
they develop deterioration in vision and promptly seek further advice. Early discontinuation of the drug is almost always followed by
recovery of eyesight. Patients who cannot understand warnings about
visual side-effects should, if possible, be given an alternative drug.
In particular, ethambutol should be used with caution in children
until they are at least 5 years old and capable of reporting symptomatic
visual changes accurately.</p><p>Visual acuity should be tested by Snellen chart before treatment
with ethambutol.</p></div><div id="_213708"><p><b><span>Streptomycin</span></b> [unlicensed] is now rarely used in
the UK except for resistant organisms. Plasma-drug concentration
should be measured in patients with impaired renal function in whom <span>streptomycin</span> must be used with great
care.</p></div><p>Drug-resistant tuberculosis should be treated
by a specialist physician with experience in such cases, and where
appropriate facilities for infection-control exist. Second-line drugs
available for infections caused by resistant organisms, or when first-line
drugs cause unacceptable side-effects, include <span>amikacin</span>, <span>capreomycin</span>, <span>cycloserine</span>,
newer macrolides (e.g. <span>azithromycin</span> and <span>clarithromycin</span>), <span>moxifloxacin</span> and protionamide (prothionamide;
no longer on UK market).</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_3900"><a href="3900.htm" title="CAPREOMYCIN">CAPREOMYCIN</a></li><li id="_3902"><a href="3902.htm" title="CYCLOSERINE">CYCLOSERINE</a></li><li id="_3904"><a href="3904.htm" title="ETHAMBUTOL HYDROCHLORIDE">ETHAMBUTOL HYDROCHLORIDE</a></li><li id="_3907"><a href="3907.htm" title="ISONIAZID">ISONIAZID</a></li><li id="_3911"><a href="3911.htm" title="PYRAZINAMIDE">PYRAZINAMIDE</a></li><li id="_14338"><a href="14338.htm" title="RIFABUTIN">RIFABUTIN</a></li><li id="_3913"><a href="3913.htm" title="RIFAMPICIN">RIFAMPICIN</a></li><li id="_201680"><a href="201680.htm" title="RIFAMPICIN WITH ISONIAZID">RIFAMPICIN WITH ISONIAZID</a></li><li id="_3923"><a href="3923.htm" title="STREPTOMYCIN">STREPTOMYCIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3894.htm">Previous: TRIMETHOPRIM</a> | <a class="top" href="3899.htm#">Top</a> | <a accesskey="]" href="3900.htm">Next: CAPREOMYCIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>